A Crossing in Therapy for Hepatitis C Virus Genotype 2 or 3: Increasing Ribavirin Dose with Shortened Duration or Reducing Ribavirin Dose with Standard Duration

被引：4

作者：

Huang, Chung-Feng ^{[1
]}

Dai, Chia-Yen ^{[1
,2
]}

Huang, Jee-Fu ^{[1
,2
,3
]}

Chunag, Wan-Long ^{[1
,2
]}

Yu, Ming-Lung ^{[1
,2
]}

机构：

[1] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan

[2] Kaohsiung Med Univ Hosp, Coll Med, Fac Internal Med, Kaohsiung, Taiwan

[3] Kaohsiung Municipal Hsiaokang Hosp, Kaohsiung, Taiwan

来源：

HEPATOLOGY | 2009年 / 49卷 / 04期

关键词：

PEGINTERFERON ALPHA-2A;

D O I：

10.1002/hep.22863

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1395 / 1396

页数：2

共 11 条

[1] Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study [J].

Dalgard, O ;

Bjoro, K ;

Hellum, KB ;

Myrvang, B ;

Ritland, S ;

Skaug, K ;

Raknerud, N ;

Bell, H .

HEPATOLOGY, 2004, 40 (06) :1260-1265

[2]

DIMARTINO V, 2008, HEPATOLOGY S, V48, pA213

[3] Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response [J].

Ferenci, Peter ;

Laferl, Hermann ;

Scherzer, Thomas-Matthias ;

Gschwantler, Michael ;

Maieron, Andreas ;

Brunner, Harald ;

Stauber, Rudolf ;

Bischof, Martin ;

Bauer, Bernhard ;

Datz, Christian ;

Loeschenberger, Karin ;

Formann, Elisabeth ;

Staufer, Katharina ;

Steindl-Munda, Petra .

GASTROENTEROLOGY, 2008, 135 (02) :451-458

[4] A randomized, prospective trial of ribavirin 400 mg/Day versus 800 mg/Day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3 [J].

Ferenci, Peter ;

Brunner, Harald ;

Laferl, Hermann ;

Scherzer, Thomas-Matthias ;

Maieron, Andreas ;

Strasser, Michael ;

Fischer, Gabriele ;

Hofer, Harald ;

Bischof, Martin ;

Stauber, Rudolf ;

Gschwantler, Michael ;

Steindl-Munda, Petra ;

Staufer, Katharina ;

Loeschenberger, Karin .

HEPATOLOGY, 2008, 47 (06) :1816-1823

[5] Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection [J].

Fried, M. W. ;

Hadziyannis, S. J. ;

Shiffman, M. ;

Messinger, D. ;

Zeuzem, S. .

JOURNAL OF HEPATOLOGY, 2008, 48 :S5-S5

[6] Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy [J].

Jensen, DM ;

Morgan, TR ;

Marcellin, P ;

Pockros, PJ ;

Reddy, KR ;

Hadziyannis, SJ ;

Ferenci, P ;

Ackrill, AM ;

Willems, B .

HEPATOLOGY, 2006, 43 (05) :954-960

[7] Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection [J].

Lagging, Martin ;

Langeland, Nina ;

Pedersen, Court ;

Farkkila, Martti ;

Buw, Mads Rauning ;

Morch, Kristine ;

Dhillon, Amar P. ;

Alsio, Asa ;

Hellstrand, Kristoffer ;

Westin, Johan ;

Norkrans, Gunnar .

HEPATOLOGY, 2008, 47 (06) :1837-1845

[8]

Rodriguez-Torres M, 2007, HEPATOLOGY, V46, p817A

[9] Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 [J].

Shiffman, Mitchell L. ;

Suter, Fredy ;

Bacon, Bruce R. ;

Nelson, David ;

Harley, Hugh ;

Sola, Ricard ;

Shafran, Stephen D. ;

Barange, Karl ;

Lin, Amy ;

Soman, Ash ;

Zeuzem, Stefan ;

Crawford, D. ;

Leggett, L. ;

Roberts, S. ;

Weltman, M. ;

Greenbloom, S. ;

Menon, K. ;

Bourliere, M. ;

Brissot, P. ;

Bronowicki, J.-P. ;

Doffoel, M. ;

Hezode, C. ;

Marcellin, P. ;

Tran, A. ;

Zarski, J.-P. ;

Avci, O. ;

Berg, T. ;

Potthoff, O. ;

Rasenack, J. ;

Ross, O. ;

von Wagner, M. ;

Ascione, A. ;

Brillanti, S. ;

Brunetto, M. ;

Bruno, R. ;

Bruno, S. ;

Cane, E. ;

Aguilar, J. ;

Barcena, R. ;

Diago, M. ;

Enriquez, J. ;

Garcia-Samaniego, J. ;

Moreno, R. ;

Planas, R. ;

Rincon, D. ;

Sola, R. ;

Testillano, M. ;

Anand, B. ;

Bilir, B. Bahri ;

Balan, V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (02) :124-134

[10] Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C [J].

von Wagner, M ;

Huber, M ;

Berg, T ;

Hinrichsen, H ;

Rasenack, J ;

Heintges, T ;

Bergk, A ;

Bernsmeier, C ;

Häussinger, D ;

Herrmann, E ;

Zeuzem, S .

GASTROENTEROLOGY, 2005, 129 (02) :522-527

← 1 2 →